Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling

Riluzole (1) is an approved therapeutic for the treatment of ALS and has also demonstrated antimelanoma activity in metabotropic glutamate GRM1 positive cell lines, a mouse xenograft assay and human clinical trials. Highly variable drug exposure following oral administration among patients, likely d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: McDonnell, Mark E., Vera, Matthew D., Blass, Benjamin E., Pelletier, Jeffrey C., King, Richard C., Fernandez-Metzler, Carmen, Smith, Garry R., Wrobel, Jay, Chen, Suzie, Reitz, Allen B.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3495316/
https://ncbi.nlm.nih.gov/pubmed/22892214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmc.2012.07.004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars